Pharmaceutical Dust
Dust Types · Dust Types overview
Pharmaceutical dust covers airborne active pharmaceutical ingredients (APIs), excipients and intermediate powders generated across manufacturing, packaging and laboratory operations. Because many APIs are biologically active at microgram-per-cubic-metre concentrations, pharmaceutical dust assessment is among the most demanding areas of occupational hygiene and requires specialist sampling and control strategies.
What pharmaceutical dust is
Pharmaceutical dust is the airborne particulate of active pharmaceutical ingredients, intermediates and excipients released during dispensing, milling, granulation, blending, compression, encapsulation, coating, packaging and cleaning operations. It also includes powders generated in formulation development, quality control laboratories and clinical trial supply.
Particle size depends on process. Micronised APIs are intentionally manufactured to single-digit micron sizes for bioavailability, which means a substantial proportion of any airborne dust is respirable. Excipients (lactose, microcrystalline cellulose, starches, sugars) span the inhalable range and contribute their own sensitisation and irritation profile.
Where pharmaceutical dust exposure occurs
Pharmaceutical dust exposure occurs wherever solid-dose powders are handled.
- API dispensing and weighing — small-scale and bulk transfer.
- Granulation, milling and blending — high-shear and fluid-bed equipment.
- Tablet compression and capsule filling — dust generation at machine interfaces.
- Coating operations — spray drying and powder coating.
- Cleaning and changeover — equipment dismantling, washing and waste handling.
- Quality control and analytical laboratories — sample preparation and dispensing.
- Packaging operations — strip and blister packing, bulk filling.
Why pharmaceutical dust assessment is different
Most APIs do not appear in HSE EH40. Manufacturers instead set an Occupational Exposure Limit (OEL) or Occupational Exposure Band (OEB) based on toxicological review — often as low as nanograms or micrograms per cubic metre. This is several orders of magnitude below typical EH40 dust limits and demands correspondingly sensitive sampling, low-detection-limit analysis and high-performance containment.
OEB classification (commonly Band 1 to Band 5) is widely used to scope containment performance targets and to select monitoring strategy. The Industrial Hygiene Containment Performance Target framework links OEB to expected airborne concentrations and to the containment performance needed at each unit operation.
Pharmaceutical dust monitoring approach
Personal and area sampling is conducted using IOM inhalable or cyclone respirable samplers as appropriate, with the analytical method selected to deliver detection limits well below the relevant OEL. For potent compounds, surrogate monitoring using a non-active marker material may be used during containment performance qualification of new equipment (a SMEPAC-style approach), with the live API confirmation conducted during the first production runs.
Sampling strategy must reflect the highest-emission steps — typically charging, discharging, sampling and equipment opening — rather than averaging across long, low-emission steady-state operations. Short-duration peak measurements are often more informative than 8-hour TWAs in containment performance work.
Respirable and inhalable fractions in pharmaceutical dust
Both fractions are relevant in pharmaceutical environments. Inhalable sampling supports comparison to total airborne API and excipient exposure. Respirable sampling characterises deep-lung dose, which for micronised APIs and inhalation products is the biologically dominant fraction. Many programmes run both fractions in parallel during commissioning and during periodic verification.
Practical pharmaceutical dust control considerations
Pharmaceutical containment is engineered, not improvised. Typical hierarchy elements include:
- Closed transfer (split-butterfly valves, isolators, RTPs) for potent APIs.
- Glovebox and isolator dispensing for OEB 4–5 compounds.
- Downflow booths and ventilated weighing enclosures for lower-band powders.
- Single-pass HEPA-filtered ventilation in cleanrooms and processing suites.
- Wash-in-place and contained cleaning to manage cleaning-phase exposure.
- Calibrated and validated containment performance verification at commissioning and periodically thereafter.
When to review pharmaceutical dust exposure
Pharmaceutical exposure assessment is normally event-driven as well as periodic. Triggers include introduction of a new API, change in OEB classification on updated toxicology, equipment modification, change of supplier-defined excipient grade, scale-up from development to commercial production, and any observed containment breach.
Frequently asked questions
Why are pharmaceutical exposure limits so low compared to general dust WELs?
Many APIs are designed to have a biological effect at microgram-per-kilogram doses. Translating that into an inhalation-based occupational exposure limit produces values in the microgram-per-cubic-metre range, far below the typical milligram-per-cubic-metre limits in EH40. The OEL or OEB reflects toxicological potency rather than nuisance dust behaviour.
What is OEB classification?
Occupational Exposure Banding groups compounds into bands (commonly 1 to 5) based on potency and toxicological hazard, with each band corresponding to a target airborne concentration range. OEBs are widely used to scope containment performance targets where a specific OEL has not yet been published.
Can a general dust monitoring programme cover pharmaceutical environments?
Usually not without adaptation. Detection limits, sampling strategy, analytical methods and containment performance verification all need to be designed around the specific OELs and OEBs in use. A general dust survey may identify obvious problems but rarely supports OEL compliance evidence for potent compounds.
Related pages